Equities analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to announce ($1.80) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.05) and the highest estimate coming in at ($1.47). Esperion Therapeutics reported earnings of ($1.29) per share during the same quarter last year, which would indicate a negative year over year growth rate of 39.5%. The firm is expected to announce its next quarterly earnings results on Wednesday, February 28th.

On average, analysts expect that Esperion Therapeutics will report full year earnings of ($7.30) per share for the current financial year, with EPS estimates ranging from ($7.63) to ($6.90). For the next year, analysts expect that the company will report earnings of ($6.39) per share, with EPS estimates ranging from ($8.54) to ($4.65). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Esperion Therapeutics.

A number of equities analysts have commented on ESPR shares. UBS Group set a $88.00 target price on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 17th. BidaskClub upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 13th. Chardan Capital increased their price objective on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, December 6th. Credit Suisse Group started coverage on shares of Esperion Therapeutics in a research note on Wednesday, January 17th. They set an “outperform” rating and a $103.00 price objective on the stock. Finally, Needham & Company LLC upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and increased their price objective for the company from $72.00 to $81.00 in a research note on Thursday, December 14th. Six analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Esperion Therapeutics has a consensus rating of “Buy” and an average target price of $77.23.

In other news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $71.79, for a total transaction of $838,076.46. Following the transaction, the director now directly owns 3,177 shares in the company, valued at $228,076.83. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 32.50% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. Tower Research Capital LLC TRC lifted its position in Esperion Therapeutics by 69,371.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 4,856 shares during the last quarter. First Mercantile Trust Co. lifted its position in Esperion Therapeutics by 56.0% during the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 1,519 shares during the last quarter. Creative Planning purchased a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $314,000. Oakmont Partners LLC purchased a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $323,000. Finally, Voya Investment Management LLC lifted its position in Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 806 shares during the last quarter. Hedge funds and other institutional investors own 92.85% of the company’s stock.

Esperion Therapeutics (NASDAQ ESPR) opened at $65.94 on Tuesday. The company has a market cap of $1,690.00, a PE ratio of -9.61 and a beta of 2.64. Esperion Therapeutics has a one year low of $13.41 and a one year high of $82.18.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/06/1-80-earnings-per-share-expected-for-esperion-therapeutics-inc-espr-this-quarter.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.